Current stage -Stage II Page 2 Posts on Medivizor
Navigation Menu

Current stage -Stage II Posts on Medivizor

2018 recommendations for the treatment of localized prostate cancer: Part II

Posted by on Sep 25, 2018 in Prostate cancer | 0 comments

In a nutshell This article reviewed treatment guidelines that have been recommended for patients with early-stage prostate cancer. Some background This analysis of existing treatment guidelines was done by the leading experts in prostate cancer research. They have made recommendations on the treatment of early-stage prostate cancer.  Methods...

Read More

Are higher doses of radiation in less time better than conventional radiotherapy for prostate cancer?

Posted by on Sep 1, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate whether dose-escalated hypo-fractionated (higher doses in less time) radiation therapy would lead to better overall survival or less chance of cancer recurrence than the conventional method. They found that there is superior cancer control associated with dose-escalated hypo-fractionated radiation therapy for...

Read More

Looking for patients with prostate cancer who have had a rise in PSA after prostate removal surgery

Posted by on Aug 31, 2018 in Prostate cancer | 0 comments

In a nutshell This trial is examining the effectiveness of different hormone therapy regimes for patients whose prostate specific antigen (PSA; a protein elevated in prostate cancer) levels rise after prostate removing surgery. The main outcome to be measured will be the change in PSA levels.   The details The best standard treatment...

Read More

Biochemical relapse-free survival outcomes for intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB)

Posted by on Mar 5, 2018 in Prostate cancer | 0 comments

In a nutshell This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment.  Some background...

Read More

The timing of first biopsy and its effect on prostate cancer reclassification

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine the influence of biopsy timing on prostate cancer reclassification during active surveillance.  The authors concluded that the timing of the first biopsy was not related to an increased risk of cancer reclassification, but prostate specific antigen (PSA) and body mass index (BMI – measured based...

Read More

Can sentinel lymph node dissection be used to identify patients who could benefit from further therapy?

Posted by on Mar 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of the study was to examine if sentinel lymph node dissection (SLND) could be used to select patients with prostate cancer who would benefit from further pelvic radiation therapy and long-term androgen deprivation therapy (ADT). It was concluded that SLND could be used as a tool to determine whether patients should have more...

Read More

Searching for men with intermediate- or high-risk prostate cancer to test a short course of very focused radiation therapy

Posted by on Feb 6, 2017 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial aims to compare conventional radiation therapy with a very focused type of radiation therapy for intermediate- and high-risk prostate cancer. The main outcome to be investigated is the number of side effects and the rate of disease recurrence at 5 years. The trial is recruiting in British Columbia, Canada. The details...

Read More